Semaglutide shows preliminary evidence of improved liver biomarkers in adolescents with obesity and suspected MASLD
Access Barriers and Variable Response to Semaglutide in Severe Adolescent Obesity: A Case Series.
Abstract
Semaglutide treatment provided preliminary evidence of improved liver biomarkers in adolescents with obesity and suspected metabolic dysfunction-associated steatotic liver disease (MASLD).